AGP Executive Report
Last update: 2 hours agoSweden Pharma Access: Rare disease patients in Sweden are waiting an average of 651 days for newly authorised orphan drugs to become available, up 153 days year-on-year, as companies move slowly on applications and reimbursement processes stay complex. AI & Chips Geopolitics: The EU is set to join the US-led “Pax Silica” push to secure advanced AI chips, raising fresh questions about supply-chain disruption and whether it undermines Europe’s strategic autonomy. EV Market Signals: Tesla registrations kept recovering across Europe in May, with big jumps in France (+655% YoY) and Sweden (+71% YoY), pointing to faster EV adoption in Scandinavia. Defense Industry Links: Sweden’s Gripen support for Ukraine continues to ripple through European supply chains, while Bell Textron is also exploring local helicopter manufacturing in Ukraine via a new legal entity. Corporate Moves: DataGuard appoints Jens Panek as CFO as it scales globally, and Paf expands onboard gaming operations by acquiring Bell Casino. Consumer & Retail: IKEA customers in the US sue for refunds tied to Trump-era tariff overcharges, while Tesla strike action in Sweden has been scaled back after two years.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![Swedish rare disease patients endure longer wait for new medicines [Advocacy Lab]](https://www.euractiv.com/content/uploads/sites/2/2026/06/GettyImages-1299083653.jpg)
